Asset Details
Do you wish to reserve the book?
Evaluation of SARS‐CoV‐2 Variants After the Declaration of End of COVID‐19 Pandemic: BA.2.86 (Pirola) and EG.5 (Eris) Variants as Global Public Health Concerns
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evaluation of SARS‐CoV‐2 Variants After the Declaration of End of COVID‐19 Pandemic: BA.2.86 (Pirola) and EG.5 (Eris) Variants as Global Public Health Concerns
Do you wish to request the book?
Evaluation of SARS‐CoV‐2 Variants After the Declaration of End of COVID‐19 Pandemic: BA.2.86 (Pirola) and EG.5 (Eris) Variants as Global Public Health Concerns
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evaluation of SARS‐CoV‐2 Variants After the Declaration of End of COVID‐19 Pandemic: BA.2.86 (Pirola) and EG.5 (Eris) Variants as Global Public Health Concerns
2025
Overview
Background and Aims Coronavirus disease 2019 (COVID‐19) caused by SARS‐CoV‐2 was first reported to the World Health Organization (WHO) on December 31, 2019. The WHO declared the COVID‐19 pandemic on March 11, 2020, after considering its impact on global public health. Therefore, we aim to assess the existing SARS‐CoV‐2 variants to understand their pathogenicity and threat after the pandemic phase of COVID‐19 so that the healthcare authorities can take prompt preventive measures. Methods We conducted a comprehensive literature search to gather information from publicly available sources. We extracted the relevant data from Google Scholar, PubMed, and Scopus. Results The virus infected over 770 million people and caused more than 6.9 million deaths worldwide. Since the inception of COVID‐19, the world has developed several therapeutic drugs and vaccines. Healthcare authorities worldwide have administered more than 13 billion vaccine doses. On May 5, 2023, the WHO declared the end of the COVID‐19 pandemic based on its global threat and impacts on human health. However, SARS‐CoV‐2 continues to mutate to create new variants that can threaten global public health anytime. We observed that BA.2.86 (Pirola) and EG.5 (Eris) variants as global public health concerns. Conclusion Genomic evolution of SARS‐CoV‐2 variants is a global public health concern for immune escape, vaccination effectiveness, therapeutic and diagnostic strategies. Therefore, we recommend close surveillance of these variants to determine their potential to cause severe disease and countermeasures.
